Showing results (231-240 of 285) with videos related to

Sort By:
Pageof 29
The New England Journal of Medicine|February 13, 1992
A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative StudyJ D Hamilton, P M Hartigan, M S Simberkoff, et al.
The Oncologist|August 25, 2018
A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced CancerS Lindsey Davis, S Gail Eckhardt, Jennifer R Diamond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2023
Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast CancerElena Shagisultanova, William Gradishar, Ursa Brown-Glaberman, et al.
Investigational New Drugs|March 12, 2017
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancersJennifer R Diamond, Barbara Goff, Martin D Forster, et al.
Frontiers in Oncology|May 31, 2017
Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast CancerAnastasia A Ionkina, John J Tentler, Jihye Kim, et al.
Breast Cancer Research : BCR|March 1, 2024
Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosisStephen G Smoots, Anna R Schreiber, Marilyn M Jackson, et al.
Breast Cancer Research and Treatment|August 18, 2020
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancerJennifer R Diamond, Carlos Becerra, Donald Richards, et al.
Cancers|March 25, 2020
Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast CancerTodd M Pitts, Dennis M Simmons, Stacey M Bagby, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 2015
A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid TumorsElena Gabriela Chiorean, Patricia LoRusso, Robert Matthew Strother, et al.
Cancer Chemotherapy and Pharmacology|July 29, 2022
A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignanciesPatrick M Boland, Christos Fountzilas, Marwan Fakih, et al.
Pageof 29